Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Henan Provincial Center for Disease Control and Prevention · National Vaccine and Serum Institute · +4 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
1,209
total citations
- FWCI
- 27.12
- Percentile
- 100%
- References
- 20
Citations per year
Authors
32- SXShengli XiaCorresponding
Henan Provincial Center for Disease Control and Prevention
- YZYuntao Zhang
National Vaccine and Serum Institute
- YWYanxia Wang
Henan Provincial Center for Disease Control and Prevention
- HWHui Wang
National Vaccine and Serum Institute
- YYYunkai Yang
National Vaccine and Serum Institute
Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Immunogenicity
- Tolerability
- Clinical trial
- Randomized controlled trial
- Internal medicine
- Adverse effect
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.